Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Trial Profile

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2015 Efficacy at 24 months, results presented at the 1st Congress of the European Academy of Neurology.
    • 30 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 03 Jun 2014 Interim results at 12 months presented at the 2014 Congress of European Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top